Navigation Links
FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
Date:4/29/2010

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC).  PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.

The FDA approval of PROVENGE is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon.  "The approval of PROVENGE is a significant step towards realizing our mission of transforming the lives of patients with cancer, and it also marks Dendreon's transformation into a commercial enterprise, ready to support the successful launch of the first personalized treatment for cancer."

Dendreon intends to make PROVENGE available through approximately 50 centers, all of which were approved PROVENGE clinical trial sites, and expects to increase capacity over the next year. The increased capacity will be a result of the anticipated licensure of its expanded New Jersey, Atlanta, Georgia and Orange County, Calif. facilities in mid-2011.

"The approval of PROVENGE, th
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... closes on Thursday, November 3, 2011.  In ... with the investment community at 5:00 p.m. Eastern Time ... to discuss the results of the quarter and other business developments. ...
... A potentially groundbreaking approach to predicting cancer patient ... electronic version of Science Magazine.  The paper describing the ... Letai and colleagues at Boston,s Dana Farber Cancer Institute. ... of the cancer cell to respond to chemotherapies. This ...
Cached Medicine Technology:Groundbreaking Approach to Predicting Cancer Patients' Response to Treatment Featured in Science Magazine 2
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
(Date:8/29/2015)... ... ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, is a ... field in the military. All too often VA hospitals treat patients with harmful and ... the VA program over a decade ago, the reality is that only 10% of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, hosted ... it will be devoting an entire short segment to the subject of diabetes. Diabetes ... globe on a daily basis, but recent advancements in medical science may prove to ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... School of Medicine (BUSM) have shown that patients ... of their degree of adherence to antihypertensive medications. ... Hypertension could have an immediate impact ... held assumption. The BUSM researchers studied ...
... for PCV-7 vaccine supported by study findings , TUESDAY, ... will be relieved by new findings that show a ... against pneumonia and other infections. , The current recommended ... of three primary doses before the age of 6 ...
... women more likely to die, but questions remain , TUESDAY, ... cancer outcomes, with black women more likely to die from ... new research shows. , , For a quarter of a ... in certain cancers. The racial disparity "first emerged about 25 ...
... Texas, July 7 Perot Systems (NYSE: PER ... case studies highlighting the success of several of its healthcare ... process solutions. The videos feature the Perot Systems clients ... Pilgrim Health Care , and Northern Arizona Healthcare . ...
... ... a New Century (The Collaboration) announced today the availability of a ... savingsdrugcard.com provides a free drug card that will help all Arizonans ... card by visiting http://www.SavingsDrugCard.com and can immediately start saving ...
... suggests proton pump inhibitors could aggravate acid trouble , TUESDAY, ... heartburn and acid reflux may actually cause heartburn. , A ... found that treatment with a proton pump inhibitor (PPI) actually ... took the medication for eight weeks. , Although the ...
Cached Medicine News:Health News:Intensive management can improve blood pressure in non-adherent hypertensive patients 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 3Health News:Video: Perot Systems Unveils Series of Healthcare Video Case Studies 2Health News:Popular Prescription Drug Discount Card Now Available in Arizona Online 2Health News:Popular Prescription Drug Discount Card Now Available in Arizona Online 3Health News:Heartburn Drugs May Contribute to the Problem 2Health News:Heartburn Drugs May Contribute to the Problem 3
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
... Radical can operate in two additional ... be removed, creating a fully featured handheld ... also be used to upgrade existing equipment ... additinal hardware or software upgrades to improve ...
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
... Oil is a clear, colorless oil ... of the UV-VIS spectrum. Resolve is ... viscosity, is non-drying and non-hardening, and ... Resolve contains no PCBs, eliminating toxicity ...
Medicine Products: